Ivermectin: it IS working for many...So why is the mainstream continuing to demonise it?

Ivermectin is an antiviral, anti-parasitic drug, which has been widely used for 30 years to treat infections such as worms, scabies, and lice in both humans and livestock. In 2015, two scientists were awarded a Nobel prize for their discovery of Ivermectin's effectiveness in treating tropical parasitic infections.

During the pandemic, doctors all around the world have had huge success using Ivermectin as a prophylactic and in treating COVID-19 patients at an early stage.

“In Argentina...they prophylaxed 800 healthcare workers [with Ivermectin]. Not one got sick. In the 400 that they didn’t prophylax with Ivermetin, 58% got sick – 237 of those 400 got sick. If you take it, you will not get sick – it has immense and potent antiviral activity.” - Pierre Kory, MD

Pierre Kory MD, speaking to a Senate Committee hearing in December 2020 about the benefits of Ivermectin as a prophylaxis and early treatment (4 mins 44)

In June 2020, researchers tested Ivermectin in vitro and found that: 2 hrs post infection with SARS-CoV-2, it was able to effect 5000-fold reduction in viral RNA at 48 hrs (i.e. it got rid of 99.98% of viral particles), concluding: "Ivermectin therefore warrants further investigation for possible benefits in humans."

Speaking to John Campbell in March 2021, Dr Tess Lawrie (director of The Evidence-Based Medicine Consultancy Ltd) outlined the results of the analysis she and her team carried out through late 2020 of clinical observations and randomised controlled trials that there had been so far.

In her initial assessment of both clinical observation and randomised controlled trials together, there was an average reduction in deaths of around 83%. In a re-analysis/review of randomised controlled trial alone, there was an average 65% reduction in death.

Tess says Ivermectin has several mechanisms of action that are antiviral, and also anti-inflammatory properties:

• Blocks the viral proteins from entering the nucleus

• Prevents the virus from impairing the immune system

• Impairs the virus’s ability to replicate

• Reduces the number of inflammatory markers

• Reduces viral load.

“It seems like a very broad spectrum antiviral.”

---

Ivermectin is cheap and certainly used to be widely available, before various high-up medical low-lifes decided to make it difficult to acquire - e.g. on 10th September, the Australian Government Department of Health introduced restrictions preventing doctors from prescribing Ivermectin for COVID - and the media and health agencies started running smear/fear campaigns around it.

Why would they do that?

Well, 2 reasons - which also apply to hydroxycholoquine (HCQ):

1. If there were existing, very effective treatments that were widely available, there would have been no need for the vaccines (or any fuss at all - the world would have just trotted on as it was)

2. Both drugs are off-patent, so are cheap to produce and don't make money for Big Pharma.

And if they were to now admit that both these repurposed drugs work - along with others, like Budesonide plus zinc, and Fluvoxamine (see 'TREATMENTS') - after they've taken away the medical licenses of doctors who were prescribing them for patients and so many untreated people have died 'from' COVID because they were told there was no treatment, there would be uproar, lawsuits, etc., etc.

So...

---

And the latest turn of events is that Merck, which was the original manufacturer and previously a large dispenser of Ivermectin, has developed a new antiviral drug, Molnupiravir, and they're hoping the FDA will grant emergency authorization for its use as the first oral treatment for COVID-19. Much like Ivermectin, it only works as a prophylactic or in the early stages of the disease.

The company is reportedly set to receive approximately $1.2 billion to supply around 1.7 million courses of Molnupiravir to the United States government, giving it a cost per treatment of $700, versus around $26 for Ivermectin! (See the separate blog on Molnupiravir.)

Three big benefits of Ivermectin over Molnupiravir (M) - (see paper published Aug 2021):

1. It inhibits cytokine production and inflammation, which has not yet been shown for M

2. It’s been found to accumulate in high quantities in the lungs, which M doesn’t

3. It lasts longer in the body than M (c.80-90 hrs versus 7 hrs)

4. It’s way cheaper

5. It has decades of data to prove how safe it is.

Real-time ongoing analysis of studies can be seen at ivmmeta.com:

---

Some studies:

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Andrew Bryant, MSc,1,* Theresa A. Lawrie, MBBCh, PhD,2 Therese Dowswell, PhD,2 Edmund J. Fordham, PhD,2 Scott Mitchell, MBChB, MRCS,3 Sarah R. Hill, PhD,1 and Tony C. Tham, MD, FRCP4

Published online June 2021

Excerpt:

Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%)

Conclusions:

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

A D Santin 1 , D E Scheim 2 , P A McCullough 3 , M Yagisawa 4 , T J Borody 5

Published online August 2021

Excerpt:

During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments.

A) Excess all-cause deaths (all ages), the national population of Peru. These decreased 14-fold from 1st August through 1st December 2020; then, after IVM use was restricted, increased 13-fold through 1st February.

Conclusion:

We believe that the evidence to date supports the worldwide extension of IVM treatments for COVID-19, complementary to immunizations. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, as reviewed [8], possibly yielding full efficacy against emerging viral mutant strains.

Finally, listen to Dr Lenny Da Costa in India, giving a 5-minute summary of his experience with Ivermectin and HCQ:

"I have colleagues who have been taking Ivermectin since March last year - one tablet a week - none of them have gotten sick. One doctor who's an infectious diseases specialist in Bombay, his entire team in one of the top specialist hospitals in Bombay takes [Ivermectin] and HCQ once a week and none of them have contracted COVID."

So, if anyone calls you a conspiracy theorist for suggesting that the response to this 'pandemic' is not about saving lives, ask them this:

If there was a safe, effective, cheap treatment for COVID (and not just one), why would governments around the world have spent the last 2 years denying it and insisting every man, woman and child gets multiple gene therapy injections?